JP6979397B2 - ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 - Google Patents

ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 Download PDF

Info

Publication number
JP6979397B2
JP6979397B2 JP2018501182A JP2018501182A JP6979397B2 JP 6979397 B2 JP6979397 B2 JP 6979397B2 JP 2018501182 A JP2018501182 A JP 2018501182A JP 2018501182 A JP2018501182 A JP 2018501182A JP 6979397 B2 JP6979397 B2 JP 6979397B2
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018501182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529635A5 (cg-RX-API-DMAC7.html
JP2018529635A (ja
Inventor
ローン，ラース，クリスチャン ビールマン
マリク，イブラヒム，ジョン
スタヴェンハーゲン，ジェフリー，ビー
クリステンセン，セーレン
エゲブジャーグ，ジャン
ジェリッツェン，アーノウト
デン ブリンク，エドワード ヴァン
パレン，ポール
ジョン，ロブ デ
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2018529635A publication Critical patent/JP2018529635A/ja
Publication of JP2018529635A5 publication Critical patent/JP2018529635A5/ja
Priority to JP2021151783A priority Critical patent/JP2022003058A/ja
Application granted granted Critical
Publication of JP6979397B2 publication Critical patent/JP6979397B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018501182A 2015-07-13 2016-07-12 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体 Active JP6979397B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021151783A JP2022003058A (ja) 2015-07-13 2021-09-17 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
GB1512215.3 2015-07-13
PCT/EP2016/066516 WO2017009327A1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021151783A Division JP2022003058A (ja) 2015-07-13 2021-09-17 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体

Publications (3)

Publication Number Publication Date
JP2018529635A JP2018529635A (ja) 2018-10-11
JP2018529635A5 JP2018529635A5 (cg-RX-API-DMAC7.html) 2019-08-15
JP6979397B2 true JP6979397B2 (ja) 2021-12-15

Family

ID=54013862

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018501182A Active JP6979397B2 (ja) 2015-07-13 2016-07-12 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体
JP2021151783A Pending JP2022003058A (ja) 2015-07-13 2021-09-17 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021151783A Pending JP2022003058A (ja) 2015-07-13 2021-09-17 ソルチリンに結合し、プログラニュリンの結合を阻害する抗体

Country Status (35)

Country Link
US (6) US10479835B2 (cg-RX-API-DMAC7.html)
EP (1) EP3322726B1 (cg-RX-API-DMAC7.html)
JP (2) JP6979397B2 (cg-RX-API-DMAC7.html)
KR (1) KR102778576B1 (cg-RX-API-DMAC7.html)
CN (3) CN107849135A (cg-RX-API-DMAC7.html)
AR (1) AR105335A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016292980B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000771A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989739A1 (cg-RX-API-DMAC7.html)
CL (2) CL2018000092A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017012988A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180002A (cg-RX-API-DMAC7.html)
DO (1) DOP2018000014A (cg-RX-API-DMAC7.html)
EA (1) EA201890038A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP18002725A (cg-RX-API-DMAC7.html)
ES (1) ES3024469T3 (cg-RX-API-DMAC7.html)
GB (1) GB201512215D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250602T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071424T2 (cg-RX-API-DMAC7.html)
IL (1) IL256503B (cg-RX-API-DMAC7.html)
JO (1) JO3710B1 (cg-RX-API-DMAC7.html)
MA (1) MA42440B1 (cg-RX-API-DMAC7.html)
MX (1) MX2018000506A (cg-RX-API-DMAC7.html)
NI (1) NI201800007A (cg-RX-API-DMAC7.html)
PE (1) PE20181014A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018500100A1 (cg-RX-API-DMAC7.html)
PL (1) PL3322726T3 (cg-RX-API-DMAC7.html)
RS (1) RS66856B1 (cg-RX-API-DMAC7.html)
RU (1) RU2735639C2 (cg-RX-API-DMAC7.html)
SV (1) SV2018005613A (cg-RX-API-DMAC7.html)
TN (1) TN2017000534A1 (cg-RX-API-DMAC7.html)
TW (1) TWI760305B (cg-RX-API-DMAC7.html)
UA (1) UA125136C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017009327A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708613B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR102530517B1 (ko) * 2018-07-13 2023-05-09 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
JP2023507846A (ja) * 2019-12-23 2023-02-27 デナリ セラピューティクス インコーポレイテッド プログラニュリン変異体
IL299329A (en) 2020-06-24 2023-02-01 Prothena Biosciences Ltd Antibodies recognizing sortilin
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0486622B1 (en) 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2380813A1 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
ES2380055T3 (es) 2002-12-20 2012-05-08 H. Lundbeck A/S Modulación de la actividad de neurotrofinas; método de escrutinio
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
SI3225251T1 (sl) 2006-12-21 2020-03-31 H. Lundbeck A/S Modulacija aktivnosti pronevrotrofinov
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
JP5715045B2 (ja) 2008-04-27 2015-05-07 ハー・ルンドベック・アクチエゼルスカベット ソルチリンに対する特異的リガンドの設計
US8420784B2 (en) 2008-05-27 2013-04-16 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor, (IL-10R) antibodies
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3165537A1 (en) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
JP6999421B2 (ja) 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR102530517B1 (ko) 2018-07-13 2023-05-09 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법

Also Published As

Publication number Publication date
KR20180030045A (ko) 2018-03-21
US20170267761A1 (en) 2017-09-21
US12331123B2 (en) 2025-06-17
TW201702273A (zh) 2017-01-16
PL3322726T3 (pl) 2025-06-23
CN114478774A (zh) 2022-05-13
IL256503A (en) 2018-02-28
HK1254356A1 (en) 2019-07-19
CO2017012988A2 (es) 2018-05-21
ECSP18002725A (es) 2018-03-31
GB201512215D0 (en) 2015-08-19
US20180305455A1 (en) 2018-10-25
CL2018000092A1 (es) 2018-07-06
MX2018000506A (es) 2018-05-11
AR105335A1 (es) 2017-09-27
US20250277040A1 (en) 2025-09-04
EP3322726C0 (en) 2025-03-12
ES3024469T3 (en) 2025-06-04
JO3710B1 (ar) 2021-01-31
EP3322726B1 (en) 2025-03-12
TWI760305B (zh) 2022-04-11
CN114478775A (zh) 2022-05-13
UA125136C2 (uk) 2022-01-19
US10428147B2 (en) 2019-10-01
NI201800007A (es) 2018-10-18
PE20181014A1 (es) 2018-06-26
US20200190188A1 (en) 2020-06-18
US10889650B2 (en) 2021-01-12
US20230159643A1 (en) 2023-05-25
SV2018005613A (es) 2018-02-23
TN2017000534A1 (en) 2019-04-12
MA42440A (fr) 2018-05-23
WO2017009327A1 (en) 2017-01-19
CN107849135A (zh) 2018-03-27
JP2022003058A (ja) 2022-01-11
HRP20250602T1 (hr) 2025-07-18
KR102778576B1 (ko) 2025-03-07
JP2018529635A (ja) 2018-10-11
ZA201708613B (en) 2021-03-31
HUE071424T2 (hu) 2025-08-28
IL256503B (en) 2022-02-01
AU2016292980B2 (en) 2022-10-06
CL2020002468A1 (es) 2021-01-29
AU2016292980A1 (en) 2018-01-18
PH12018500100A1 (en) 2018-07-30
EP3322726A1 (en) 2018-05-23
US20210269524A1 (en) 2021-09-02
CA2989739A1 (en) 2017-01-19
EA201890038A1 (ru) 2018-06-29
US10479835B2 (en) 2019-11-19
RU2018100824A3 (cg-RX-API-DMAC7.html) 2020-01-17
RU2735639C2 (ru) 2020-11-05
CR20180002A (es) 2018-04-09
MA42440B1 (fr) 2025-05-30
US11548950B2 (en) 2023-01-10
RS66856B1 (sr) 2025-06-30
DOP2018000014A (es) 2018-04-15
BR112018000771A2 (pt) 2018-09-25
RU2018100824A (ru) 2019-08-13

Similar Documents

Publication Publication Date Title
JP6979397B2 (ja) ソルチリンに結合し、プログラニュリンの結合を阻害する抗体
JP7012004B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
JP7563975B2 (ja) 治療のための薬剤、使用及び方法
HK1254356B (en) Antibodies that bind to sortilin and inhibit the binding of progranulin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210917

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211018

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211115

R150 Certificate of patent or registration of utility model

Ref document number: 6979397

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250